BetaKine data

CTRX (Santa Clara, Calif.) released its final analysis of a 36-patient closed-label Phase II study of BetaKine to treat venous stasis ulcers. Patients in the treatment arm received 2.5 µg/cm 2 of BetaKine delivered in a collagen sponge plus standard wound dressing; patients in the second arm received standard wound dressing; patients in the third arm received standard wound dressing plus the sponge without drug.

The rate of wound closure in the treatment arm was 1.9 cm 2/week, similar to the rate of 2.1 cm 2/week seen in the company’s previous Phase I/II open-label trial, which used a dose of 0.5 µg/cm 2 of BetaKine. Thus there was no benefit to using a higher dose of drug. ...